Accelerate Diagnostics Inc (AXDX) : Oracle Investment Management Inc scooped up 5,271 additional shares in Accelerate Diagnostics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 5,092,727 shares of Accelerate Diagnostics Inc which is valued at $133,684,084.Accelerate Diagnostics Inc makes up approximately 19.66% of Oracle Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Geode Capital Management boosted its stake in AXDX in the latest quarter, The investment management firm added 13,159 additional shares and now holds a total of 211,903 shares of Accelerate Diagnostics Inc which is valued at $5,064,482.Tiaa Cref Investment Management boosted its stake in AXDX in the latest quarter, The investment management firm added 1,169 additional shares and now holds a total of 70,423 shares of Accelerate Diagnostics Inc which is valued at $1,545,785. Quantbot Technologies Lp added AXDX to its portfolio by purchasing 1,981 company shares during the most recent quarter which is valued at $40,412.Trust Co Of Vermont reduced its stake in AXDX by selling 500 shares or 50.0% in the most recent quarter. The Hedge Fund company now holds 500 shares of AXDX which is valued at $11,625.
Accelerate Diagnostics Inc closed down -0.4 points or -1.55% at $25.4 with 2,48,538 shares getting traded on Monday. Post opening the session at $25.8, the shares hit an intraday low of $24.9 and an intraday high of $25.95 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Accelerate Diagnostics Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform the Accelerate ID/AST System (the ID/AST System) intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST) which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.